NYU Langone Health is moving its early-stage biotech incubator from Manhattan to Innolabs in Long Island City.
BioLabs@NYU Langone, which has been located at 180 Varick St., signed a 46,000-square-foot lease for a new facility at Innolabs, located at 45–18 Court Square.
The new lease is separate from NYU Langone’s deal for 104,000 square feet at Innolabs struck in 2024 for four research-based programs.
“The new site will build on our years of joint success in attracting and supporting the next wave of life-science startups in New York City,” said Johannes Fruehauf, BioLabs founder and CEO, in a statement. “BioLabs@NYU Langone will play a pivotal role in the Innolabs ecosystem, fueling and supporting discovery, innovation and economic growth for the city and helping accelerate critical solutions to the patients who need them.”
“This new space will offer startups, including those that spin out from our own labs, expanded access to the resources, community and infrastructure they need to drive innovation, scale ideas and make a lasting impact on human health and wellbeing around the world,” added Vicki Suna, executive vice president and vice dean for real estate development and facilities at NYU Langone.
Innolabs is a 267,000-square-foot property centered around life-science companies. It was developed by a partnership of Boston-based King Street Properties and Manhattan-based GFP Real Estate.
“This addition reinforces Innolabs as the destination in NYC for top-tier life sciences companies,” said Ed Jaram, senior director at King Street, in the statement.
Amenities at Innolabs include a lobby café, event space, secure bike storage, and locker rooms with showers and storage.
“Being able to provide flexible, high-quality space for early-stage life science companies is something we take great pride in,” GFP co-CEO Brian Steinwurtzel said.
Based on Boston, BioLabs has locations in 17 markets throughout the U.S., Europe and Japan. Its worldwide coworking lab facilities are operated in partnership with LabCentral and MBC-BioLab.
From Kevin Smith at New York Business Journal